A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers

Colin Stott, Linda White, Stephen Wright, Darren Wilbraham, Geoffrey Guy, Colin Stott, Linda White, Stephen Wright, Darren Wilbraham, Geoffrey Guy

Abstract

Abstract: This Phase I study aimed to assess the potential drug-drug interactions (pharmacokinetic [PK] and safety profile) of Δ9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray (Sativex (®), nabiximols) in combination with cytochrome P450 (CYP450) inducer (rifampicin) or inhibitors (ketoconazole or omeprazole). Thirty-six healthy male subjects were divided into three groups of 12, and then randomized to one of two treatment sequences per group. Subjects received four sprays of THC/CBD (10.8/10 mg) alongside single doses of the CYP3A and 2C19 inducer rifampicin (600 mg), CYP3A inhibitor ketoconazole (400 mg) or CYP2C19 inhibitor omeprazole (40 mg). Plasma samples were analyzed for CBD, THC and its metabolite 11-hydroxy-THC (11-OH-THC). A single dose of four sprays of THC/CBD spray (10.8/10 mg) following repeated doses of rifampicin (600 mg) reduced the Cmax and AUC of all analytes. Cmax reduced from 2.94 to 1.88 ng/mL (-36%), 1.03 to 0.50 ng/mL (-52%) and 3.38 to 0.45 ng/mL (-87%) for THC, CBD and 11-OH-THC, respectively compared to single dose administration of THC/CBD spray alone. Ketoconazole co-administration with THC/CBD spray had the opposite effect, increasing the Cmax of the respective analytes from 2.65 to 3.36 ng/mL (+27%), 0.66 to 1.25 ng/mL (+89%) and 3.59 to 10.92 ng/mL (+204%). No significant deviations in Cmax or AUC for any analyte were observed when THC/CBD spray was co-administered with omeprazole. THC/CBD spray was well tolerated by the study subjects both alone and in combination with rifampicin, ketoconazole and omeprazole. Evaluation of the PKs of THC/CBD spray alone and in combination with CYP450 inhibitors/inducers suggests that all analytes are substrates for the isoenzyme CYP3A4, but not CYP2C19. On the basis of our findings, there is likely to be little impact on other drugs metabolized by CYP enzymes on the PK parameters of THC/CBD spray, but potential effects should be taken into consideration when co-administering THC/CBD spray with compounds which share the CYP3A4 pathway such as rifampicin or ketoconazole.

Trials registration: NCT01323465.

Keywords: Cannabidiol; Cytochrome P450; Delta-9-tetrahydrocannabinol; Nabiximols†; Sativex ®†; THC/CBD spray.

Figures

Figure 1
Figure 1
Mean(+SD)plasma concentrations of THC(a),CBD(b)and 11-OH-THC(c)over time after administration of a single dose(4 sprays)of THC/CBD(n =11)or THC/CBD spray in combination with multiple dose(2 x 300 mg)administration of Rifampicin(n = 12).
Figure 2
Figure 2
Mean(+SD)plasma concentrations of THC(a),CBD(b)and 11-OH-THC(c)over time after administration of a single dose(4 sprays)of THC/CBD(n =11)or THC/CBD spray in combination with multiple dose(2 x 200 mg)administration of Ketoconazole (n= 11).
Figure 3
Figure 3
Mean(+SD)plasma concentrations of THC(a),CBD(b)and 11-OH-THC(c)over time after administration of a single dose(4 sprays)of THC/CBD(n =11)or THC/CBD spray in combination with multiple dose(2 x 20 mg)administration of Omeprazole (n= 12).

References

    1. Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta(9)-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol. 2005;70:1096–103. doi: 10.1016/j.bcp.2005.07.007.
    1. Chen J, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicriob. 2006;5:3. doi: 10.1186/1476-0711-5-3.
    1. Constantinescu CS, Sarantis N. Long-term open-label treatment with Sativex ® in patients with multiple sclerosis. Mult Scler. 2006;12:111.
    1. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57:107–16.
    1. DiPiro JT. Pharmacotherapy: A Pathophysiologic Approach. 4. Stamford, Conn: Appleton & Lange; 1999. pp. 29–30.
    1. Indiana University Department of Medicine. 2012.
    1. Bioanalytical Method Validation issued by the U.S Department of Health and Human Services Food and Drug Administration. 2012.
    1. Drug development and drug interactions: table of substrates, inhibitors and inducers. 2012.
    1. Foltz RL, McGinnis KM, Chinn DM. Quantitative measurement of delta 9-tetrahydrocannabinol and two major metabolites in physiological specimens using capillary column gas chromatography negative ion chemical ionization mass spectrometry. Biochemical MS. 1983;10(5):316–23.
    1. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20(3):153–67. doi: 10.2133/dmpk.20.153.
    1. Goodall CR, Basteyns BJ. A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood. J Anal Tox. 1995;19:419–26. doi: 10.1093/jat/19.6.419.
    1. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 2008;21(1):70–83. doi: 10.1021/tx700079z.
    1. Howlett AC, Barth F, Bonner T. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161–202. doi: 10.1124/pr.54.2.161.
    1. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4:1770–804. doi: 10.1002/cbdv.200790152.
    1. Johnson JR, Burnell-Nugent M, Lossignol D. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC: CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage. 2010;39(2):167–79. doi: 10.1016/j.jpainsymman.2009.06.008.
    1. Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. J Pain Symptom Manage. 2012. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractive to strong opioid analgesia.
    1. Kemp MP, Abukhalaf IK, Manno JE, Manno BR, Alford DD, Abusada GA. Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolites in plasma and urine using GC-MS. J Anal Tox. 1995;19:91–285. doi: 10.1093/jat/19.2.91.
    1. Langford RM, Mares J, Novotna A, Vachova M, Novakova I, Notcutt W, Ratcliffe S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984–97. doi: 10.1007/s00415-012-6739-4.
    1. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84–112.
    1. Miller JC, Miller JN. Statistics for analytical Chemistry. 1992.
    1. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133:210–20. doi: 10.1016/j.pain.2007.08.028.
    1. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 2000;13(4):421–3.
    1. Pertwee RG. Cannabinoids and Multiple Sclerosis. Mol Neurobiol. 2007;36:45–59. doi: 10.1007/s12035-007-0005-2.
    1. Porteney R, Ganae-Motan ED, Allende S. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49. doi: 10.1016/j.jpain.2012.01.003.
    1. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;8:283–91.
    1. Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta-9- tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068–79. doi: 10.1016/j.clinthera.2007.09.013.
    1. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. BJP. 2011;163:1344–64. doi: 10.1111/j.1476-5381.2011.01238.x.
    1. Stott CG, White L, Wright S, Wilbraham D, Guy GW. Eur J Clin Pharmacol. 2012. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    1. Whittle BA, Guy GW, Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Therapeutics. 2001;1(3–4):183–205. doi: 10.1300/J175v01n03_12.
    1. Yamaori S, Kushihara M, Yamamoto I, Watanabe K. Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol. 2010;79:1691–8. doi: 10.1016/j.bcp.2010.01.028.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe